DeCure for Neurodegeneration with brain iron accumulation 2B
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for neurodegeneration with brain iron accumulation 2B — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNeurodegeneration with brain iron accumulation 2B maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for neurodegeneration with brain iron accumulation 2b is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
A 2013 report on the Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) initiative states that neurodegeneration with brain iron accumulation (NBIA) is a group of rare hereditary disorders characterised by high brain iron, with many cases showing early childhood onset and rapid progression to disability and death. The most frequent form is pantothenate kinase-associated neurodegeneration (PKAN). The report notes that there is no proven therapy to halt or reverse PKAN or any other NBIA form, and that the absence of adequately powered randomised clinical trials is due to the rarity of the disease, the lack of patient registries, and the fragmentation of therapeutic research worldwide, not a lack of therapeutic options.
A 2019 review describes NBIA as a set of neurodegenerative disorders that includes very rare monogenetic diseases, heterogeneous in onset and clinical symptoms, but sharing specific brain iron deposition in the basal ganglia visible on radiological and histopathological examination. Fifteen genes have been identified as causative for NBIA, but only two code for iron-proteins; the rest code for proteins not involved in iron management. The review states that how iron participates in the pathogenetic mechanism of most NBIA remains unclear, essentially because of the lack of experimental models that fully recapitulate the human phenotype.
A 2014 case report describes a 13-year-old girl with mitochondrial membrane protein-associated neurodegeneration treated with an iron-chelating agent. Brain iron content was monitored by R2 relaxometry, R2* relaxometry, and quantitative susceptibility mapping. The highly increased brain iron content slowly decreased in the substantia nigra but remained stable for globus pallidus. The estimated iron content was higher by R2* compared to R2 and quantitative susceptibility mapping, a finding not previously observed in the brain of healthy volunteers.
What is still missing are experimental models that fully recapitulate the human phenotype, adequately powered randomised clinical trials, patient registries, and a unified global research effort. The mechanism by which iron contributes to most NBIA forms remains unclear, and the single reported case of iron-chelating therapy showed only a partial and region-specific reduction in brain iron content, with no data on clinical outcomes.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Neuroscience · 2018 · 110 citations · open access
The Involvement of Iron in Traumatic Brain Injury and Neurodegenerative Disease
AbstractTraumatic brain injury (TBI) consists of acute and long-term pathophysiological sequelae that ultimately lead to cognitive and motor function deficits, with age being a critical risk factor for poorer prognosis. TBI has been recently linked to the development of neurodegenerative diseases later in life including Alzheimer's disease, Parkinson's disease, chronic traumatic encephalopathy, and multiple sclerosis. The accumulation of iron in the brain has been documented in a number of neurodegenerative diseases, and also in normal aging, and can contribute to neurotoxicity through a variety of mechanisms including the production of free radicals leading to oxidative stress, excitotoxicity and by promoting inflammatory reactions. A growing body of evidence similarly supports a deleterious role of iron in the pathogenesis of TBI. Iron deposition in the injured brain can occur via hemorrhage/microhemorrhages (heme-bound iron) or independently as labile iron (non-heme bound), which is considered to be more damaging to the brain. This review focusses on the role of iron in potentiating neurodegeneration in TBI, with insight into the intersection with neurodegenerative conditions. An important implication of this work is the potential for therapeutic approaches that target iron to attenuate the neuropathology/phenotype related to TBI and to also reduce the associated risk of developing neurodegenerative disease.
Pharmaceuticals · 2019 · 91 citations · open access
Neurodegeneration with Brain Iron Accumulation Disorders: Valuable Models Aimed at Understanding the Pathogenesis of Iron Deposition
AbstractNeurodegeneration with brain iron accumulation (NBIA) is a set of neurodegenerative disorders, which includes very rare monogenetic diseases. They are heterogeneous in regard to the onset and the clinical symptoms, while the have in common a specific brain iron deposition in the region of the basal ganglia that can be visualized by radiological and histopathological examinations. Nowadays, 15 genes have been identified as causative for NBIA, of which only two code for iron-proteins, while all the other causative genes codify for proteins not involved in iron management. Thus, how iron participates to the pathogenetic mechanism of most NBIA remains unclear, essentially for the lack of experimental models that fully recapitulate the human phenotype. In this review we reported the recent data on new models of these disorders aimed at highlight the still scarce knowledge of the pathogenesis of iron deposition.
Annals of Clinical and Translational Neurology · 2014 · 27 citations · open access
Brain iron quantification by MRI in mitochondrial membrane protein‐associated neurodegeneration under iron‐chelating therapy
AbstractTherapeutic trials for Neurodegeneration with Brain Iron Accumulation have aimed at a reduction of cerebral iron content. A 13-year-old girl with mitochondrial membrane protein-associated neurodegeneration treated with an iron-chelating agent was monitored by R2 relaxometry, R2* relaxometry, and quantitative susceptibility mapping to estimate the brain iron content. The highly increased brain iron content slowly decreased in the substantia nigra but remained stable for globus pallidus. The estimated iron content was higher by R2* compared to R2 and quantitative susceptibility mapping, a finding not previously observed in the brain of healthy volunteers. A hypothesis explaining this discrepancy is offered.
Treat Iron-Related Childhood-Onset Neurodegeneration (TIRCON) - an integrated strategy under FP7 to improve research, treatment, and care in neurodegeneration with brain iron accumulation
AbstractAims: Neurodegeneration with brain iron accumulation (NBIA) is a clinically and genetically heterogeneous group of rare hereditary neurodegenerative disorders characterized by high levels of brain iron. Many NBIA cases are characterized by early childhood onset and rapid progression to disability and death. The most frequent form of NBIA is pantothenate kinase-associated neurodegeneration (PKAN). Currently, there is no proven therapy to halt or reverse PKAN or any other form of NBIA. This is especially unfortunate as both the iron accumulation in NBIA and the biochemical defect in PKAN are predicted to be amenable to drug-based treatment. Thus, the absence of adequately powered randomized clinical trials is not due to a lack of therapeutic options but to the rarity of the disease, the lack of patient registries, and the fragmentation of therapeutic research worldwide.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
